Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism

(2020) Elizabeth A. Killion et al.   Nature Communications

Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals

(2019) Lærke S. Gasbjerg et al.   DIABETES

Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery

(2019) Pierre Larraufie et al.   Cell Reports

The incretin system in healthy humans: The role of GIP and GLP-1

(2019) Jens Juul Holst   METABOLISM-CLINICAL AND EXPERIMENTAL

Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition

(2019) Kentaro Kaneko et al.   JOURNAL OF CLINICAL INVESTIGATION

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats

(2019) Sara Baldassano et al.   Frontiers in Endocrinology

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies For The Treatment Of Obesity, Do Agonists = Antagonists?

(2019) Elizabeth A Killion et al.   ENDOCRINE REVIEWS

GIP analogues and the treatment of obesity-diabetes

(2019) Clifford J. Bailey   PEPTIDES

Pharmacological antagonism of the incretin system protects against diet-induced obesity

(2019) Berit Svendsen et al.   Molecular Metabolism

Human GIP(3-30)NH 2 inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors

(2018) Maria Buur Nordskov Gabe et al.   BIOCHEMICAL PHARMACOLOGY

Incretin hormones: Their role in health and disease

(2018) Michael A. Nauck et al.   DIABETES OBESITY & METABOLISM

Gut hormone polyagonists for the treatment of type 2 diabetes

(2018) Sara J. Brandt et al.   PEPTIDES

Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents

(2018) Lærke Smidt Gasbjerg et al.   PEPTIDES

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

(2018) Elizabeth A. Killion et al.   Science Translational Medicine

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

(2018) Piotr A. Mroz et al.   Molecular Metabolism

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

Discovery, characterization, and clinical development of the glucagon-like peptides

(2017) Daniel J. Drucker et al.   JOURNAL OF CLINICAL INVESTIGATION

Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

(2017) Valérie Turcot et al.   NATURE GENETICS

N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor

(2016) L S Hansen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity

(2016) R. Burcelin et al.   Obesity Reviews

Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion

(2016) Frank Reimann et al.   Journal of Diabetes Investigation

Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice

(2015) Michael O. Boylan et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors

(2015) A H Sparre-Ulrich et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Role of Gut Adaptation in the Potent Effects of Multiple Bariatric Surgeries on Obesity and Diabetes

(2015) Randy J. Seeley et al.   Cell Metabolism

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

(2015) V. Pathak et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

TCF1 links GIPR signaling to the control of beta cell function and survival

(2015) Jonathan E Campbell et al.   NATURE MEDICINE

Effect of Modified Roux-en-Y Gastric Bypass Surgery on GLP-1, GIP in Patients with Type 2 Diabetes Mellitus

(2015) Shao-Wei Xiong et al.   Gastroenterology Research and Practice

Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions

(2014) D. Nasteska et al.   DIABETES

Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies

(2013) S. Calanna et al.   DIABETOLOGIA

Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor

(2013) Peter Ravn et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance

(2012) N. B. Jørgensen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Bariatric Surgery versus Conventional Medical Therapy for Type 2 Diabetes

(2012) Geltrude Mingrone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucose-Dependent Insulinotropic Polypeptide Reduces Fat-Specific Expression and Activity of 11 -Hydroxysteroid Dehydrogenase Type 1 and Inhibits Release of Free Fatty Acids

(2011) O. Gogebakan et al.   DIABETES

Gastric Bypass Surgery Enhances Glucagon-Like Peptide 1-Stimulated Postprandial Insulin Secretion in Humans

(2011) M. Salehi et al.   DIABETES

Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide

(2010) Barry D. Kerr et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

(2010) K. J. Hare et al.   DIABETES

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans

(2010) M. Asmar et al.   DIABETES

Amelioration of Insulin Requirement in Patients Undergoing Duodenal Bypass for Reasons Other than Obesity Implicates Foregut Factors in the Pathophysiology of Type II Diabetes

(2010) Emmanuel E. Zervos et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

(2010) Elizabeth K Speliotes et al.   NATURE GENETICS

Impact of Different Bariatric Surgical Procedures on Insulin Action and  -Cell Function in Type 2 Diabetes

(2009) E. Ferrannini et al.   DIABETES CARE

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes

(2008) Nigel Irwin et al.   BIOLOGICAL CHEMISTRY

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

(2008) Matthew C. Althage et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of Weight Loss by Gastric Bypass SurgeryVersusHypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes

(2008) Blandine Laferrère et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vaccination against GIP for the Treatment of Obesity

(2008) Alma Fulurija et al.   PLoS One